Result of AGM
Updated : 12:53
19 June 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Result of AGM
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. All resolutions were passed on a show of hands. The results of the proxy voting for the AGM is set out below.
Resolution | Total votes For1 | % of votes cast2 | Total Votes Against | % of votes cast2 | Total Votes Cast3 | % of issued share capital | Votes Withheld4 | |
1 | To receive the annual report and audited accounts for the year ended 31 December 2018 | 16,362,457 | 99.99 | 1,134 | 0.01 | 16,363,591 | 16.13 | 0
|
2 | To re-elect Luke Cairns as a director of the Company | 16,332,857 | 99.99 | 1,134 | 0.01 | 16,333,991 | 16.10 | 29,600 |
3 | To elect John Chiplin as a Director of the Company | 16,332,857 | 99.99 | 1,134 | 0.01 | 16,333,991 | 16.10 | 29,600 |
4 | To elect Chris Britten as a Director of the Company | 16,332,857 | 99.99 | 1,134 | 0.01 | 16,333,991 | 16.10 | 29,600 |
5 | To re-appoint Saffery Champness LLP as auditor and authorise directors to determine their remuneration | 16,334,857 | 99.85 | 25,000 | 0.15 | 16,359,857 | 16.12 | 3,734 |
6 | Authority to allot shares | 16,331,657 | 99.82 | 30,200 | 0.18 | 16,361,857 | 16.12 | 1.734 |
7 | Authority to disapply pre-emption rights | 16,330,457 | 99.97 | 5,334 | 0.03 | 16,335,791 | 16.10 | 27,800 |
Notes:
1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Total Votes Cast do not include withheld votes
4. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution
Enquiries:
N4 Pharma Plc Nigel Theobald, CEO |
Via Scott PR
|
Allenby Capital Limited James Reeve/Asha Chotai
| Tel: +44(0)203 328 5656 |
Scott PR Georgia Smith
|
Tel: +44(0)1477 539 539
|
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.